RL
Relay Therapeutics
RLAY·NASDAQCambridge MAFounded 2016400 employees
Mid CapbiotechPublicOncology
Platform: Motion Design
Market Cap
$3B
All Drugs
3
Clinical Trials
7
Failed / Terminated
1
FDA Approved
0
Stock Price & Catalysts (RLAY)
Loading RLAY stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| RLA-6817 | RLA-6817 | Phase 3 | 4 | TIGIT | BCC | ||
| RLA-8772 | RLA-8772 | Phase 2 | 1 | MALT1 | PAH | ||
| Sovacagene | RLA-4825 | Phase 1/2 | 2 | Menin | Prostate CaSMA |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (6)